MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/hematolrep16020035

Медицинская библиотека · Hematology reports · 2024

Blinatumomab in Children with MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia: A Report of 11 Cases.

Wang Yi-Lun, Chang Tsung-Yen, Wen Yu-Chuan, Yang Shu-Ho, Hsiao Yi-Wen, Chiu Chia-Chi, Chen Yu-Chieh, Hu Ruei-Shan, Chen Shih-Hsiang, Jaing Tang-Her, Hsiao Chih-Cheng

Клинический случайСтатьяПеревод пока не подготовлен

Аннотация

Background/

Objectives

Relapsed B-cell acute lymphoblastic leukemia (B-ALL) remains an unresolved matter of concern regarding adverse outcomes. This case study aimed to evaluate the effectiveness of blinatumomab, with or without door lymphocyte infusion (DLI), in treating measurable residual disease (MRD)-positive B-ALL.

Methods

All patients who received blinatumomab salvage therapy were included in this study. Eleven patients were included in the study. All patients were evaluated for MRD-negativity.

Results

Before starting blinatumomab therapy, seven patients tested positive for MRD, three tested negative, and one had refractory disease. Hematopoietic cell transplantation (HCT) was reserved for five patients with persistent MRD. Six patients became MRD-negative and subsequent HCT was not performed. Only two patients relapsed; one patient died of relapse, and the other one received carfilzomib-based therapy and was MRD-negative thereafter. Nine patients were MRD-negative at a median follow-up of 28 months (15-52 months). Two of three MRD-positive post-transplant patients remained in complete molecular remission after preemptive DLI at the last follow-up date. In the first salvage, blinatumomab may achieve complete remission and bridging to HCT in pediatric patients with end-of-induction MRD-positive B-cell precursor ALL.

Conclusions

The decision on how to treat post-transplant relapse continues to affect survival outcomes. Blinatumomab combined with DLI may extend the armamentarium of release options for high-risk pediatric patients. This approach is encouraging for high-risk ALL patients who are MRD-positive post-transplantation.

Для цитирования: Wang Yi-Lun, Chang Tsung-Yen, Wen Yu-Chuan, Yang Shu-Ho, Hsiao Yi-Wen, Chiu Chia-Chi, Chen Yu-Chieh, Hu Ruei-Shan, Chen Shih-Hsiang, Jaing Tang-Her, Hsiao Chih-Cheng. Blinatumomab in Children with MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia: A Report of 11 Cases.. Hematology reports. 2024. DOI: 10.3390/hematolrep16020035.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.